BRIM Biotechnology’s lead candidate BRM421 for Dry Eye Disease shows promising results in Phase II clinical trials
Taipei, Taiwan, June 29th, 2021, BRIM Biotechnology, Inc. (“BRIM”) is pleased to advise that the Type C meeting with the US Food and Drug Administration (FDA) for the further development of lead candidate BRM421 for Dry Eye Disease (DED) has taken…